Shanghai Junshi Biosciences Co. Ltd (SHJBF PINK) stock market data APIs
$1.9576
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Shanghai Junshi Biosciences Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Prev. Close
1.9576
Open
1.9576
High
1.9576
Low
1.9576
52 wk Range
1.24-1.97
Market Cap
3 411 M
Shares Outstanding
260 M
Revenue
2 331 M
EPS
-0.024
Beta
0.644
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shanghai Junshi Biosciences Co. Ltd data using free add-ons & libraries
Get Shanghai Junshi Biosciences Co. Ltd Fundamental Data
Shanghai Junshi Biosciences Co. Ltd Fundamental data includes:
- Net Revenue: 2 331 M
- EBITDA: -932 068 352
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-26
- EPS/Forecast: NaN
Get Shanghai Junshi Biosciences Co. Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shanghai Junshi Biosciences Co. Ltd News
New
Is Junshi Biosciences an Opportunity After Its 230% Rally Into 2025?
Thinking about whether to jump in, hold on, or step back from Shanghai Junshi Biosciences? You are not alone. In the past year, this stock has gone through the kind of transformation that gets investo...
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
Junshi Biosciences SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical compa...
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
Junshi Biosciences SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical ...
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
Junshi Biosciences SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical compan...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
